文献速递病毒性肝炎

布来韦肽联合富马酸替诺福韦二吡呋酯治疗乙型肝炎病毒和丁型肝炎病毒共感染患者的安全性和疗效(MYR202):一项多中心、随机、平行组、开放标签、2期试验

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
PubMed 文献 · Lancet Infect Dis · 2022-09-13

MYR202是一项多中心、随机、平行组、开放标签2期试验,纳入120例慢性丁型肝炎病毒(HDV)感染成人(含59例肝硬化),随机接受布来韦肽2 mg、5 mg、10 mg联合富马酸替诺福韦二吡呋酯(TDF)或单用TDF治疗24周。第24周时,布来韦肽各剂量组达到主要终点(HDV RNA不可测或下降≥2 log10 IU/mL)的比例显著高于单用TDF组;停药至第48周HDV RNA反弹。

要点

  • 布来韦肽2 mg、5 mg、10 mg联合TDF治疗24周,HDV RNA应答率均显著高于单用TDF。
  • 停药24周后(第48周)HDV RNA浓度出现反弹。
  • 常见不良事件包括无症状胆汁盐升高及丙氨酸氨基转移酶和天冬氨酸氨基转移酶升高。

核心结论

  • 布来韦肽在24周内诱导HDV RNA显著下降,但停药后HDV RNA浓度反弹。
  • 作者认为应研究更长的治疗疗程和联合治疗方案。

研究设计与样本

  • MYR202为多中心、平行组、随机、开放标签、2期试验(NCT03546621;EudraCT 2016-000395-13)。
  • 纳入18-65岁慢性HDV感染成人,包括肝硬化患者及有PegIFNα治疗禁忌或治疗无效者,来自德国4家和俄罗斯12家医院。
  • 120例患者(59例肝硬化)按1:1:1:1随机接受布来韦肽2 mg(n=28)、5 mg(n=32)、10 mg(n=30)每日一次皮下注射联合TDF 245 mg每日一次口服,或单用TDF 245 mg每日一次口服(n=30),疗程24周。
  • 主要终点为第24周HDV RNA不可测或下降≥2 log10 IU/mL,在改良意向治疗人群(随机后至少接受一次研究药物)中分析;HDV RNA监测至第48周。
  • 安全性分析纳入所有至少接受一剂布来韦肽或TDF的患者。

主要发现

  • 2016年2月16日至2016年12月8日筛查171例慢性HDV感染患者,51例因排除标准不合格,120例(59例肝硬化)入组。
  • 第24周达到主要终点:布来韦肽2 mg组15/28例(54%,95%CI 34-73;vs 单用TDF p<0.0001),5 mg组16/32例(50%,32-68;p<0.0001),10 mg组23/30例(77%,58-90;p<0.0001),单用TDF组1/28例(4%,0.1-18)。
  • 第48周(布来韦肽停药24周后)HDV RNA反弹,第24周至第48周中位变化:2 mg组1.923 log10 IU/mL(IQR 0.566-2.485),5 mg组1.732 log10(0.469-2.568),10 mg组2.030 log10(1.262-2.903)。
  • 无与治疗相关的死亡;严重不良事件:布来韦肽5 mg组3例(9%),10 mg组2例(7%),TDF组1例(4%)。
  • 常见治疗中出现的不良事件包括无症状胆汁盐升高及丙氨酸氨基转移酶和天冬氨酸氨基转移酶升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV) and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing authorisation by the European Medical Agency for treatment of chronic hepatitis D virus infection. We investigated the antiviral activity of bulevirtide in patients chronically infected with HBV and hepatitis D virus. METHODS: MYR202 (ClinicalTrials.gov, NCT03546621; EudraCT, 2016-000395-13) was a multicentre, parallel-group, randomised, open-label, phase 2 trial. Adults (aged 18-65 years) with chronic hepatitis D virus infection, including patients with cirrhosis and patients who had contraindications to PegIFNα treatment or for whom treatment did not work, were eligible and were enrolled from four hospitals in Germany and 12 hospitals in Russia. Patients were randomly assigned (1:1:1:1) to receive 2 mg (n=28), 5 mg (n=32), or 10 mg (n=30) subcutaneous bulevirtide once per day with tenofovir disoproxil fumarate (TDF; 245 mg once per day orally) or TDF alone (245 mg once per day orally; n=30) for 24 weeks. Randomisation was done using a digital block scheme with stratification, consisting of 480 randomisation numbers separated into 30 blocks. The primary endpoint was undetectable hepatitis D virus RNA or 2 log10 IU/mL or higher decline in hepatitis D virus RNA at week 24, which was analysed in the modified intention-to-treat population, including patients who received study medication at least once after randomisation. Hepatitis D virus RNA concentrations were monitored until week 48. Safety was assessed for all patients who received at least one dose of bulevirtide or TDF. FINDINGS: Between Feb 16, 2016, and Dec 8, 2016, 171 patients with chronic hepatitis D virus infection were screened; 51 were ineligible based on the exclusion criteria and 120 patients (59 with cirrhosis) were enrolled. At week 24, 15 (54%, 95% CI 34-73) of 28 patients achieved undetectable hepatitis D virus RNA or a 2 log10 IU/mL or more decline in hepatitis D virus RNA (p<0·0001 vs TDF alone) with 2 mg bulevirtide, 16 (50%, 32-68) of 32 with 5 mg bulevirtide (p<0·0001), and 23 (77%, 58-90) of 30 with 10 mg bulevirtide (p<0·0001), versus one (4%, 0·1-18) of 28 with TDF alone. By week 48 (24 weeks after bulevirtide cessation), hepatitis D virus RNA concentrations had rebounded, with median changes from week 24 to week 48 of 1·923 log10 IU/mL (IQR 0·566-2·485) with 2 mg bulevirtide, 1·732 log10 (0·469-2·568) with 5 mg bulevirtide, and 2·030 log10 (1·262-2·903) with 10 mg bulevirtide. There were no deaths associated with treatment. Three (9%) patients in the bulevirtide 5 mg group, two (7%) patients in the bulevirtide 10 mg group, and one (4%) patient in the TDF group had serious adverse events. Common treatment-emergent adverse events included asymptomatic bile salt increases and increases in alanine aminotransferase and aspartate aminotransferase. INTERPRETATION: Bulevirtide induced a significant decline in hepatitis D virus RNA over 24 weeks. After cessation of bulevirtide, hepatitis D virus RNA concentrations rebounded. Longer treatment durations and combination therapies should be investigated. FUNDING: Hepatera LLC, MYR GmbH, and the German Centre for Infection Research, TTU Hepatitis.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wedemeyer H, Schöneweis K, Bogomolov P, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2022. PMID: 36113537. doi:10.1016/S1473-3099(22)00318-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。